Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is a 24 week double-blind study in which subjects will be randomized 2:1 to receive
Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo.
Xolair injections will occur every 2-4 weeks. Aspirin desensitization will occur several
weeks later. One month after desensitization, the final visit will occur in the GCRC.
We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior to the
aspirin desensitization will reduce severity of aspirin-induced reaction.